Clostridium Difficile

Researchers identify first human antibodies capable of neutralizing toxins

Published in TB and Outbreaks Week, April 8th, 2003

Epicyte Pharmaceutical, Inc., has announced that its scientists have identified the first pair of fully human antibodies capable of neutralizing the Clostridium difficile enterotoxins A and B.

"This discovery addresses a serious unmet need in health care," said Dr. Larry Zeitlin, Epicyte's lead scientist on the C. difficile project. "C. difficile infection is potentially fatal, and is very expensive to treat using current therapeutics. The Toxin B monoclonal antibody we have identified is the first monoclonal antibody from any source capable of neutralizing the toxin. Researchers have previously described Toxin A neutralizing monoclonals, but we...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-04-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry